Aaron Ring, M.D., Ph.D.

Aaron is the Founder of Simcha Therapeutics and a widely-recognized leader in cytokine engineering for which he was named to Endpoints “20 under 40 in Biopharma in 2022” and Nature Biotechnology’s “Top 20 Translational Researchers of 2020.” He led the development of decoy-resistant IL-18 in his laboratory at the Yale School of Medicine where he is an Associate Professor of Immunobiology.

Tom Boone, M.S.

Tom has more than 40 years of accomplishments in the discovery and development of protein therapeutics. Tom worked at Amgen for 28 years and served in positions of increasing responsibility in growing Amgen Protein Sciences to an organization of over 300 researchers across five different sites. His career at Amgen began in 1981 as a bench scientist with the isolation and cDNA cloning of novel cytokines and growth factors including G-CSF. He was also responsible for expressing, purifying, and formulating many of Amgen’s recombinant proteins. Tom developed proprietary processes used to produce recombinant G-CSF and other therapeutic candidates for clinical applications. Tom was the first Vice President of Amgen Protein Science. Tom was the lead scientist in the development of Nplate®, a treatment of thrombocytopenia. His critical role in the discovery and process development of G-CSF (Neupogen) is widely recognized. Tom has Masters degrees in Microbiology from UCLA and Soil Science from UC Davis. Tom has recently helped start several companies and has helped them license in clinical stage molecules. He is currently a consultant or scientific advisor for more than 30 companies, providing both strategic and technical guidance.

Mike Mangone, Ph.D.

Mike has spent more than 15 years in strategic, operational and drug development roles in the biotech and life science space. Most recently, he was Vice President of Business Development and Operations at BridgeBio (BBIO) where he advanced two late-stage portfolio companies, Phoenix Tissue Repair and Origin Biosciences. At Origin, Mike managed operations through clinical development; oversaw FDA and EMA approvals; and directed corporate strategy for the launch of Nulibry, BridgeBio’s first commercial asset. Prior, Mike consulted for a wide range of biotech, pharma and private equity clients on projects spanning corporate, portfolio and commercial strategy, and business development in the oncology, inflammation and immunology, and autoimmunity disease spaces among other areas. Mike also spent time at Flagship Pioneering helping create early-stage platform companies centered on breakthrough science, such as Ring Therapeutics.

Mike is a scientist by training and developed small molecule inhibitors targeting key oncogenic and inflammatory pathways at the Center for Lymphoid Malignancy at Columbia University. He received his Ph.D. in Pathobiology working on cancer vaccine development at NYU School of Medicine and earned an A.B. in molecular biology from Princeton University.

Roland Meier, M.D., Ph.D

Roland has over 20 years of experience in clinical practice, research, and industry in all phases of drug development. He has served in immuno-oncology leadership roles at Bristol Myers Squibb, Eli Lilly, and most recently at Kyowa Kirin. Earlier in his career, Roland worked in Medical Affairs, Drug Safety, and Clinical Development. Roland has worked on multiple therapeutics from Phase 1 to Phase 4. He has contributed to commercially available drugs including Jevtana, Kadcyla, Herceptin, Avastin, Venclexta, Empliciti, and Poteligeo. His immuno-oncology contributions includes checkpoint inhibitors Opdivo and Yervoy and various immune-stimulatory T-cell agonists including urelumab (4-1BB and GITR); and other immuno-modulatory agents including IDO inhibitors and RNA vaccines.

During his postdoctoral fellowship at the Lawrence Berkeley National Laboratory, Roland investigated the role of the tumor microenvironment on tumor initiation and progression and characterized a protein that could mediate resistance to targeted therapy in breast cancer.

After Roland graduated with an MD from the University of Zurich, Switzerland, he worked as a resident at the Children’s Hospital of Zurich and subsequently at the University Hospital in Lausanne, Switzerland where he pursued his passion for research and was awarded an M.D., Ph.D.

Beatrice McQueen, Ph.D.

Beatrice has 20+ years of industry experience in research and development, operations, finance and business development. Beatrice was appointed a Simcha executive since its inception in 2018 accountable for all aspects of the company – G&A, Corporate Strategy and R&D, including manufacturing, preclinical & clinical development, regulatory and quality. Prior to Simcha, she served on the commercial team at PPD. Before PPD, Beatrice established and led Beatrice Perotti Inc in 2006, a consulting firm, full time for 12 years until 2017, providing consulting services to start ups and established biotech companies. Beatrice started consulting after 12 years of product development and finance experience in leadership positions in PKDM, product strategy/early development, strategic business operations and finance at Pfizer and Amgen. 

Beatrice graduated with a Ph.D. in Pharmaceutical Chemistry – Pharmacokinetics & Drug Metabolism from the University of California, San Francisco, and an E.M.B.A. from UCLA Anderson School of Management. Beatrice also had a Project Management Certificate from CalTech and was an Amgen certified Six Sigma Black Belt.

Sanuj Ravindran, M.D.

Sanuj has spent more than 20 years in strategic and operational roles across the life science industry, both as an investor and company builder. Most recently, he served as CEO-in-residence at BridgeBio (BBIO) where he was chief executive officer of PellePharm, and executive chair of Phoenix Tissue Repair. In these roles, Sanuj led both companies’ growth, directed strategy, secured significant partnerships, and advanced pipeline programs in oncology and rare skin diseases through mid- and late-stage clinical trials. Before this, he served as chief business officer at aTyr Pharma (LIFE), a clinical-stage protein therapeutics company focused on tRNA synthetases. Prior to that, Sanuj was senior vice president of corporate development at The Medicines Company (MDCO), where he led multiple transactions totaling more than $2 billion in potential value. Sanuj began his biotech career as a venture capitalist for 10 years with Burrill & Company, Radius Ventures, and Asian Healthcare Fund. 

Sanuj was previously a practicing physician, board-certified in Internal Medicine, having completed his residency training at Thomas Jefferson University Hospital. He received his bachelor’s degree from Northwestern University, his doctorate in medicine from Jefferson Medical College, and his master’s of business administration from the Kellogg School of Management.